Physician profile
Robert J Robinson
NPI 1164502985
$7,588.26
in general payments reported to CMS, 2019-2025
35 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,608 · 2020: $1,805 · 2021: $605 · 2022: $767 · 2023: $946 · 2024: $507 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,831.60 | 2019-2024 | Farxiga, Lokelma, Airsupra |
| Glaxosmithkline, LLC. | $791.49 | 2019-2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $629.62 | 2019-2023 | Spravato |
| Lilly USA, LLC | $615.02 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $610.18 | 2019-2023 | Repatha |
| Ironshore Pharmaceuticals INC. | $379.41 | 2019 | |
| Novo Nordisk INC | $332.81 | 2019-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $250.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.94 | 2019-2023 | Xifaxan |
| Pfizer INC. | $179.11 | 2019-2020 | |
| Allergan, INC. | $170.94 | 2019-2020 | |
| Amarin Pharma, INC. | $167.16 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.18 | 2019-2022 | |
| Abbott Laboratories | $150.00 | 2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $136.94 | 2023 | Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $123.37 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $103.60 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $90.30 | 2021 | |
| Orexo US, INC. | $85.27 | 2019-2020 | |
| Eisai INC. | $72.57 | 2019 | |
| Merck Sharp & Dohme LLC | $72.22 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $64.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.12 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.86 | 2019-2020 | |
| Abbvie INC. | $51.47 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $46.43 | 2019 | |
| Astellas Pharma US INC | $28.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.57 | 2019 | |
| Sanofi Pasteur INC. | $16.75 | 2019 | |
| Adlon Therapeutics L.P. | $14.13 | 2020 | |
| Antares Pharma, INC. | $13.85 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.72 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.